Compare

Agios Pharmaceuticals, Inc. vs Nektar Therapeutics vs Ocular Therapeutix, Inc vs Aytu Biopharma, Inc

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearAgios Pharmaceuticals, Inc.
AGIO
Nektar Therapeutics
NKTR
Ocular Therapeutix, Inc
OCUL
Aytu Biopharma, Inc
AYTU
Year ended2025-12-312025-12-312025-12-312026-06-30
Revenue$54.03M$55.23M$51.95M$57.57M
Revenue growth (YoY)+48.0%-43.9%-18.5%-13.3%
Gross margin88.3% (computed)n/a87.3% (computed)64.0%
Operating margin-873.9%-253.7%-519.8%-14.4%
Net margin-764.0%-297.1%-511.9%-24.8%
Net income-$412.78M-$164.08M-$265.94M-$14.25M
EPS (Diluted)-$7.12-$9.73-$1.42n/a
Operating cash flow-$372.98M-$208.51M-$204.88M$3.28M
Free cash flow-$377.29M-$208.68M-$216.89M$3.25M
Cash & equivalents$89.13M$15.12M$737.06M$26.31M
Total assets$1.30B$280.41M$808.06M$105.01M
Total liabilities$104.11M$190.57M$153.75Mn/a
Shareholders' equity$1.19B$89.83M$654.31M$35.27M
Return on year-end equity-34.6%-182.6%-40.6%-40.4%
Shares outstanding58.45M20.38M215.93M10.73M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearAgios Pharmaceuticals, Inc.Nektar TherapeuticsOcular Therapeutix, IncAytu Biopharma, Inc
Latest$54.03M
Ended 2025-12-31
$55.23M
Ended 2025-12-31
$51.95M
Ended 2025-12-31
$57.57M
Ended 2026-06-30
1 year earlier$36.50M
Ended 2024-12-31
$98.43M
Ended 2024-12-31
$63.72M
Ended 2024-12-31
$66.38M
Ended 2025-06-30
2 years earlier$26.82M
Ended 2023-12-31
$90.12M
Ended 2023-12-31
$58.44M
Ended 2023-12-31
$65.18M
Ended 2024-06-30
3 years earlier$14.24M
Ended 2022-12-31
$92.06M
Ended 2022-12-31
$51.49M
Ended 2022-12-31
$107.40M
Ended 2023-06-30
4 years earlier$0
Ended 2021-12-31
$101.91M
Ended 2021-12-31
$43.52M
Ended 2021-12-31
$96.67M
Ended 2022-06-30